<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963362</url>
  </required_header>
  <id_info>
    <org_study_id>GLA5PR-107</org_study_id>
    <nct_id>NCT03963362</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of GLA5PR Tablet According to the Renal Function</brief_title>
  <official_title>Clinical Study to Evaluate Pharmacokinetics of GLA5PR Tablet According to the Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evauate pharmacokinetics of GLA5PR tablet according to the renal function
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Cmax of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUClast of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>AUClast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72 hours after administration</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2beta of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>t1/2beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>Vz/F</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg as 60~89 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg over 90 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg over 90 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 150 mg as 60~89 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 150 mg over 90 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 150 mg over 90 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg as 30~59 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR tablet 75 mg</intervention_name>
    <description>GLARS-NF3 tablet</description>
    <arm_group_label>Administration of GLA5PR 75 mg as 30~59 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 75 mg as 60~89 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 75 mg over 90 mL/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR tablet 150 mg</intervention_name>
    <description>GLARS-NF3 tablet</description>
    <arm_group_label>Administration of GLA5PR 150 mg as 60~89 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 150 mg over 90 mL/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject who, at the time of screening, are the age between 19 and 64 years

          -  Subject who has body weight more than 50 kg (45 kg in women), and less than 80 kg

          -  Subject who normal renal function of the creatinine clearance calculated by
             Cockcroft-Gault equation over 90 mL/min

          -  Subject who the mild renal function of the creatinine clearance between 60 and 89
             mL/min calculated by Cockcroft-Gault equation

          -  Subject who the moderate renal patient of the creatinine clearance between 30 and 59
             mL/min calculated by Cockcroft-Gault equation

          -  Subject who is clinically no significant by a medical history, physical, and
             psychological examination

          -  Subject who clinically no significant a vital sign with Investigator's judgment

          -  Subject who has result of diagnostic laboratory test excluding the items described in
             exclusion criteria of the 13, and 14, and judged to be clinically no significant when
             medically by investigator

          -  Subject who has consented to use a combination of effective contraceptive methods or
             medically appropriate contraceptive methods from the first administration of the
             clinical trial drug to the end of the clinical trial (when testing for final safety
             evaluation) and not to provide sperm or egg

          -  Subject who is negative the serum and urine hCG test, and is not to pregnant and
             feeding

          -  Subject who signed and dated the informed consent form after understanding fully to
             hear a detailed explanation in the clinical trial

          -  Subject who is accept to the post-study visit and to be willing to providing of
             collection the blood, and urine

        Exclusion Criteria:

          -  Subject who is any history of gastrointestinal disease (e.g., Crohn's disease, and
             others), and surgery (except for simple appendectomy or repair of a hernia), which can
             influence the absorption of investigational products

          -  Subject who has a history of hypersensitivity or clinically significant
             hypersensitivity reactions to drugs or other drugs (aspirin, antibiotics, etc.) that
             contain components of the clinical trial drug or components of the same class (except
             for inactive allergic rhinitis)

          -  Subject who is genetic problem such as galactose intolerance, or Lapp lactose
             dehydrogenase deficiency, or glucose-galactose uptake disorder

          -  Subject with the exclusion criteria of 1 to 3, or a significant disease (epilepsy,
             etc.) and past disease that is considered difficult to participate in clinical trials
             according to the investigator's judgement

          -  Subject who had whole blood donation within 60 days or component blood donation within
             30 days before the first administration of the investigational product, or transfusion
             within 60 days before the first administration

          -  Subject who has participated in any other clinical trials and had medication within
             180 days prior to the first administration of investigational product

          -  Subject who has taken any ethical-the-counter drug or has taken any over-the-counter
             drug within 14 days before the screening visit, except to the taken the
             prior-medication for the disease treatment

          -  Subject who has taken any oriental medicines or any dietary supplements within 30
             days, before the screening visit

          -  Subject who has taken any heavy drinking within 30 days before the screening visit
             (&gt;21 units/week)

          -  Subject who has taken a food expected to have an effect on the clinical trial within 7
             days, before the screening visit; The food of contained in caffeine (&gt; 2 times/day)
             The products containing grapefruit (&gt; 2 times/day)

          -  Subject who has shown positive reaction to drugs that may be abused from a urine drug
             screening

          -  Subject who is positive result in smoking or urine nicotine test within 30 days,
             before the screening visit

          -  Subject who is positive result in serum test (hepatitis type B test, hepatitis type C
             test, Human Immunodeficiency Virus (HIV) test, and syphilis test), during the
             screening period

          -  Subject who showed the following findings in the tests conducted during the screening
             period;

          -  Less than the lower normal limit (LNL) in the Hb.

          -  In excess of 1.5 times the upper normal limit (UNL) in the hepatic enzyme (AST and
             ALT), and the alkaline phosphatase values

          -  In excess of 1.5 times the upper normal limit (UNL) in the total bilirubin

          -  Subject who is QTc &gt; 450 msec in ECG or a clinically significant abnormal rhythm
             during the screening period

          -  Subject who is not eligible person for the clinical trial according to the
             investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minchang Kwon, Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>GL PharmTech Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Hyuk Jung, MS</last_name>
    <phone>82-31-739-5220</phone>
    <phone_ext>404</phone_ext>
    <email>jhjung@glpt.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeong-Seok Lim, MD, Ph D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyeong-Seok Lim, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLA5PR</keyword>
  <keyword>Renal function</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

